Adenine

Adenine

SCHEMBL4595803

Nc1ncnc2[nH]cnc12.[H+]

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 7/20 0.47
PI4K2B Q8TCG2 7/20 0.47
PI4K2A Q9BTU6 7/20 0.47
PI4KB Q9UBF8 7/20 0.47
XDH P47989 2/20 0.47
LRRK2 Q5S007 2/20 0.47
LMNA P02545 1/20 0.47
DRD3 P35462 1/20 0.47
ADORA2A P29274 4/20 0.39
ADORA1 P30542 4/20 0.39
RET P07949 1/20 0.38
ERAP1 Q9NZ08 1/20 0.38
GDA Q9Y2T3 2/20 0.33
PNP P00491 1/20 0.33
BTK Q06187 1/20 0.33
ADORA2B P29275 2/20 0.32
PARP1 P09874 1/20 0.32
PDPK1 O15530 1/20 0.32
PRKCI P41743 1/20 0.32
MAP4K4 O95819 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Adenine SCHEMBL3414603 0.98 PI4KA (0.48) PI4KAPI4K2BPI4K2API4KBXDH
Adenine SCHEMBL3416954 0.98 PI4KA (0.48) PI4KAPI4K2BPI4K2API4KBXDH
Adenine SCHEMBL3413247 0.98 PI4KA (0.48) PI4KAPI4K2BPI4K2API4KBXDH
Adenine SCHEMBL8110 0.98 PI4KA (0.48) PI4KAPI4K2BPI4K2API4KBXDH
Adenine SCHEMBL2895675 0.95 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBXDH
Adenine SCHEMBL11798390 0.95 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBXDH
Adenine SCHEMBL7204509 0.95 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBXDH
Adenine SCHEMBL20485928 0.95 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBXDH
Adenine SCHEMBL10868999 0.95 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBXDH
Adenine SCHEMBL1370888 0.95 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113039191-B Nucleotide analogues 奇异基因组学系统公司 2024-07-16 CN disclosed
EP-4396372-A2 AMPLIFICATION OLIGONUCLEOTIDES Singular Genomics Systems, Inc. (US) 2024-07-10 EP disclosed
EP-4396339-A1 METHODS FOR DIFFERENTIATING MODIFIED NUCLEOBASES Singular Genomics Systems, Inc. (US) 2024-07-10 EP disclosed
US-20240200041-A1 Modified Pyrococcus Polymerases and Uses Thereof FIRST-CITIZENS BANK & TRUST COMPANY 2024-06-20 US disclosed
WO-2024128688-A1 NOVEL BIOMARKERS FOR DIAGNOSIS OR PROGNOSIS OF INTERSTITIAL CYSTITIS AND USE THEREOF 사회복지법인 삼성생명공익재단 2024-06-20 WO disclosed
US-12006540-B2 Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-06-11 US disclosed
US-20240182875-A1 ENGINEERED PYROCOCCUS ENZYMES AND USES THEREOF FIRST-CITIZENS BANK & TRUST COMPANY 2024-06-06 US disclosed
US-11999999-B2 Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-06-04 US disclosed
US-20240174709-A1 NUCLEOTIDE ANALOGUES FIRST-CITIZENS BANK & TRUST COMPANY 2024-05-30 US disclosed
US-11987709-B2 Silicon containing detectable compounds and uses thereof Singular Genomics Systems, Inc. (US) 2024-05-21 US disclosed
EP-0642347-A1 USE OF 2-HALO ADENINE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST CHRONIC MYELOGENOUS LEUKEMIA THE SCRIPPS RESEARCH INSTITUTE (US) 1995-03-15 EP disclosed
EP-0626853-A1 USE OF SUBSTITUTED ADENINE DERIVATIVES FOR TREATING MULTIPLE SCLEROSIS THE SCRIPPS RESEARCH INSTITUTE (US) 1994-12-07 EP disclosed
US-5310732-A Such as cladribine THE SCRIPPS RESEARCH INSTITUTE (US) 1994-05-10 US disclosed
WO-1993023058-A1 USE OF 2-HALO ADENINE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST CHRONIC MYELOGENOUS LEUKEMIA THE SCRIPPS RESEARCH INSTITUTE (US) 1993-11-25 WO disclosed
WO-1993016706-A1 USE OF SUBSTITUTED ADENINE DERIVATIVES FOR TREATING MULTIPLE SCLEROSIS THE SCRIPPS RESEARCH INSTITUTE (US) 1993-09-02 WO disclosed
US-5106837-A Administering 2-halo-2'-deoxyadenosine such as cladribine; treating autohemolytic anemia THE SCRIPPS RESEARCH INSTITUTE (US) 1992-04-21 US disclosed
US-5057421-A Thin film membrane enzyme/coemzyme reactor and method of using same BRUNSWICK CORPORATION (US) 1991-10-15 US disclosed
EP-0364559-A4 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS 1991-01-09 EP disclosed
EP-0364559-A1 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS. SCRIPPS CLINIC RES (US) 1990-04-25 EP disclosed
WO-1989008658-A1 SUBSTITUTED ADENINE DERIVATIVES USEFUL AS THERAPEUTIC AGENTS SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1989-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11999999-B2 Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis POLRMT, RNGTT, MTR PI4KA 3170/4885PI4K2B 2653/4885PI4K2A 2403/4885
US-12006540-B2 Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis POLRMT, RNGTT, MTR PI4KA 3170/4885PI4K2B 2653/4885PI4K2A 2403/4885
US-20240174709-A1 NUCLEOTIDE ANALOGUES NUDT1, POLN, TYMP PI4KA 1295/4885PI4K2B 1790/4885PI4K2A 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.